TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05077215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-007
Description: A Repurposed Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection
Description: Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection
Description: Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Capsules
Description: Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib Capsules
Description: Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.
Study: NCT05977413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAC Notification
Description: Patient-Clinician CAC Notification. The CAC Notification intervention sent to both patients and clinicians has five features. 1) Results of a high CAC score (\>100 AU) detected on the patient's prior chest CT, 2) an image of the patient's CAC clearly marked, 3) a recommendation to have a patient-clinician risk discussion, 4) specific statin dosing recommended by guidelines, and 5) a link to the prevention gidelines.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinician Guideline Reminder
Description: The Guideline Reminder intervention sent to primary care clinicians has five features. 1) A reminder that all patients should have their 10-year risk for ASCVD events calculated, 2) a figure of the recommended treatment algorithm according to ASCVD 10-year risk, 3) a nudge that patients who qualify for lung cancer screening are generally at high ASCVD risk, 4) a reminder that patients at elevated risk should be engaged in shared decision-making to discuss statin therapy and other preventive interventions, and 5) access to the complete ACC/AHA Primary Prevention Guidelines and the online 10-year ASCVD risk estimator.
Study: NCT04742634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEC-C
Description: * DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEC-C
Description: * DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEC-C
Description: * DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyeloSeq-HD
Description: -Laboratory test developed at Washington University School of Medicine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyeloSeq-HD
Description: -Laboratory test developed at Washington University School of Medicine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyeloSeq-HD
Description: -Laboratory test developed at Washington University School of Medicine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyeloSeq-HD
Description: -Laboratory test developed at Washington University School of Medicine
Study: NCT06340685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Open-label design with doses of triheptanoin up to 4.0 gm/kg triheptanoin
Study: NCT06501534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: Tablets, Once a day (QD), Per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI128
Description: Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI128
Description: Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI128
Description: Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral
Study: NCT04991402

Intervention type: DEVICE
Intervention: Dolutegravir-based antiretroviral therapy
Description: This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy.~This is considered standard of care.

Intervention type: DEVICE
Intervention: Dolutegravir-based antiretroviral therapy
Description: This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy.~This is considered standard of care.
Study: NCT05862766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: The dose will consist of isatuximab 10 mg/kg actual body weight given weekly for the first 4 weeks, followed by 10 mg/kg biweekly for an additional 4 doses. Isatuximab is a clear, colorless to slightly yellow solution. It is supplied as 100 mg/5 mL or 500 mg/25 mL single-dose vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: The dose will consist of isatuximab 10 mg/kg actual body weight given weekly for the first 4 weeks, followed by 10 mg/kg biweekly for an additional 4 doses. Isatuximab is a clear, colorless to slightly yellow solution. It is supplied as 100 mg/5 mL or 500 mg/25 mL single-dose vials.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow biopsy
Description: Bone marrow biopsy at the time of lung transplantation and at approximately 1 month following completion of therapy. Initial bone marrow biopsy to be performed during the lung transplant operation and to be collected from the sternum by the operating surgeon. Follow-up bone marrow biopsy to be completed by credentialed hematologist during a regularly scheduled follow-up bronchoscopy with standard procedural anesthesia sedation.
Study: NCT06211179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Mavacamten intact oral capsule
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Mavacamten intact oral capsule
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Mavacamten intact oral capsule
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Mavacamten open capsule in suspension
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Mavacamten open capsule in suspension
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Mavacamten open capsule in suspension
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)
Description: Specified dose on specified days
Study: NCT04943744

Intervention type: DEVICE
Group type: OTHER
Intervention: Entero-tracker
Description: Esophageal STRING test (Entero-tracker)

Intervention type: DEVICE
Group type: OTHER
Intervention: Entero-tracker
Description: Esophageal STRING test (Entero-tracker)

Intervention type: DEVICE
Group type: OTHER
Intervention: Entero-tracker
Description: Esophageal STRING test (Entero-tracker)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: omalizumab
Description: Used in the parent study

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: omalizumab
Description: Used in the parent study

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dupliumab
Description: Used in the parent study

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dupliumab
Description: Used in the parent study
Study: NCT05899257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersive Training using EYME
Description: Psychological assessment based on the RGT with EYME-Explore Your Meanings, a digital platform to explore the structure and content of personal identity with Virtual Reality.
Study: NCT05666323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Text Messaging (TM1)
Description: Receives single text message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Text Messaging (TM1)
Description: Receives single text message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Text Messaging (TM1)
Description: Receives single text message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Description: Receive phone calls from trained MAPS counselors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Description: Receive phone calls from trained MAPS counselors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Text Messaging (TM+)
Description: Receives multiple scheduled text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Text Messaging (TM+)
Description: Receives multiple scheduled text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Text Messaging (TM+)
Description: Receives multiple scheduled text messages
Study: NCT05924022

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Treatment Full
Description: Participants in this active treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT)100% oxygen and 2.0 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric Oxygen Treatment Sham
Description: Participants in the sham condition arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT) 21% oxygen and 1.3 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session receiving less than a fully pressurized 100% oxygen dose.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Treatment Partial Pressure
Description: Participants in this partial treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT)100% oxygen and 1.3 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
Study: NCT04694534

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serious game
Description: The serious game is accessible via an online platform, on a tablet: 4 20-minutes activities sessions per week must be carried out.~The program format in the serious game form makes possible to simultaneously understand a large number of cognitive functions.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Usual HAS care
Description: The control group patients will follow the care they need, according to the HAS recommendations. Non-specific cognitive activities notebooks will be provided to them. They will be instructed to perform the 4 20-minutes sessions per week for 4 months.
Study: NCT06573996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TENS Device
Description: Description: The active TENS device, specifically the Dental Pain Eraser (DPE), is applied to the gums for about 2.5 minutes. This intervention is designed to modulate nerve activity to reduce pain during orthodontic alignment and leveling.~Arms Associated:~Arm 1: Upper Right Side - Active TENS Device Arm 3: Lower Right Side - Active TENS Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TENS Device
Description: Description: The active TENS device, specifically the Dental Pain Eraser (DPE), is applied to the gums for about 2.5 minutes. This intervention is designed to modulate nerve activity to reduce pain during orthodontic alignment and leveling.~Arms Associated:~Arm 1: Upper Right Side - Active TENS Device Arm 3: Lower Right Side - Active TENS Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intervention 2: Placebo/Sham Device
Description: The placebo/sham device is identical in appearance to the TENS device but does not deliver electrical stimulation. It is applied to the gums for 2.5 minutes to serve as a control.~Arms Associated:~Arm 2: Upper Left Side - Placebo/Sham Device Arm 4: Lower Left Side - Placebo/Sham Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intervention 2: Placebo/Sham Device
Description: The placebo/sham device is identical in appearance to the TENS device but does not deliver electrical stimulation. It is applied to the gums for 2.5 minutes to serve as a control.~Arms Associated:~Arm 2: Upper Left Side - Placebo/Sham Device Arm 4: Lower Left Side - Placebo/Sham Device
Study: NCT05520034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: The participants received a 45mins, face-to-face group health education after enrollment and during the 6th month by a RA nurse. Participants received the same health education over the phone call if the patient and family caregiver could not come for any reason. They also received a digital BP machine, a salt-measurement spoon, a medication box, and a recording notebook for monitoring. The intervention group receives health education above and reminder telephone calls provided by research assistant nurses every month (1st month to 3rd month: twice a month, and 4th month to 12th month: once a month)
Study: NCT06007872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracardiac Echocardiography (ICE)
Description: ICE will be used to guide trans-septal puncture and to guide device implant.
Study: NCT05420935

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IgG group
Description: Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IgE group
Description: Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a bone marrow sampling

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IgG group + IgE group
Description: * a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml~* a bone marrow sampling
Study: NCT06098469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback sessions
Description: 10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment
Study: NCT05356702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Health Assessment
Description: Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. They will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
Study: NCT05844501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Ondansetron 8 mg orally twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo orally twice daily for 28 days
Study: NCT05758116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg d1,q21d\*17
Study: NCT04977375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation Therapy
Description: Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Standard of care surgical resection of tumor on Day 10-28
Study: NCT06537726

Intervention type: DIAGNOSTIC_TEST
Intervention: Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
Description: Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
Description: Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
Description: Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
Description: Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.
Study: NCT05724277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: A 15-minute mindfulness meditation will be conducted by the meditation instructor researcher.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A 10-minute virtual reality experience will be provided by using virtual reality glasses.
Study: NCT06522906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Strengthening
Description: Patients will be offered five video consultations (30-45 minutes each) with a physical therapist over 3 months. The physical therapist will prescribe an exercise program individualized to the OA patient that will include strengthening exercises (2 quadriceps, 1 hip/gluteal, 1 hamstrings/gluteal, 1 calf, and 1 other) to be performed at home 3x/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Physical Activity
Description: The general program will consist of four 60-minute live video consultations conducted by a promotora. The first three sessions will be conducted every 2 weeks, with a booster session occurring one month later. The promotora will help dyads set achievable personalized physical activity goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Administered by a promotora, treatment will include 4 live video educational sessions about OA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Administered by a promotora, treatment will include 4 live video educational sessions about OA
Study: NCT06543953

Intervention type: DEVICE
Group type: OTHER
Intervention: HearCare MED-EL App
Description: The main task of the HearCare MED-EL App is to perform technical checks on both implants and audio processors and create backups of audio processor configurations so that these configurations can be written on to an empty audio processor of the same type.
Study: NCT04844814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe
Description: Anakinra 100 mg/d subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 30 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Prednisone
Description: Placebo of Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Anakinra
Description: Placebo of Anakinra
Study: NCT06345313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Day Group
Description: Patient group that will be operated on between 08.00-12.00

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Night Group
Description: Patient group that will be operated on between 18.00-22.00
Study: NCT05831774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention - Intraosseous (IO) administration of vancomycin
Description: * IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision~* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* Injection will take place into the proximal humerus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control - Standard IV administration of vancomycin
Description: Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for primary total shoulder arthroplasty patients. This includes IV abx (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[6,7\] generally 1000-1750mg in 500mL NS).